The company’s conjugate QLS5132 has produced intriguing, but early results.

BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.